Zheng Wei, Connect Bio CEO
May 3, 2022 04:06 PM EDTUpdated 04:47 PM
R&D

Ex­clu­sive: Con­nect Bio­phar­ma re­ports a PhII fail for Zeposia chal­lenger, and ex­ecs ap­pear ready to punt

Max Gelman

Senior Editor

Con­nect Bio­phar­ma is at­tempt­ing to play catch-up to big­ger names in the S1P mod­u­la­tor race, such as Bris­tol My­ers Squibb and Pfiz­er, now that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Al­con tried to sink Au­ri­on's IPO in 'Valen­tine's Day mas­sacre,' new law­suits say

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times